Barely Significant

Excerpts

514,629 sentences

nominally significantP < 0.051.0× alphagold
At several time points, including weeks 12, 24, and 36, a trend toward improvement in epratuzumab‐treated patients over placebo was seen, with nominally significant differences between the placebo + standard therapy group and the epratuzumab + standard therapy treatment groups (i.e., P < 0.05 versus placebo, without adjustment for multiple comparisons).
marginally significantp = 0.0501.0× alphagold
The difference in frequency of CC, CT and TT genotypes was marginally significant among male PACG cases (37.25, 37.25 and 25.50%) as compared to control males (26.03, 52.97 and 21.00%) ( p = 0.050, OR CT = 0.49; 95% CI = 0.24–1.00) but not among POAG males (27.23%; 58.41 and 14.36%) ( p = 0.818, OR CT = 1.05; 95% CI = 0.67–1.65).